Report Open Access

Statistical review of Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial

Wilkinson, Jack; Dahly, Darren

The following review has been prepared in collaboration with members of the MRC-NIHR Trials Methodology Research Partnership. The reviewers named above, and other, unnamed discussants of the paper, are all qualified statisticians with experience in clinical trials. Our objective is to provide a rapid review of publications, preprints and protocols from clinical trials of COVID-19 treatments, independent of journal specific review processes. We aim to provide timely, constructive, focused, clear advice aimed at improving both the research outputs under review, as well as future studies. Given our collective expertise (clinical trial statistics) our reviews focus on the designs of the trials and other statistical content (methods, presentation and accuracy of results, inferences). Here we review Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial, by Chen et al. https://www.medrxiv.org/content/10.1101/2020.03.17.20037432v2

Files (589.9 kB)
Name Size
Review 20_03_21_001(1).pdf
md5:caec1dce19b27f4f178192988f71de3e
589.9 kB Download
4,402
2,557
views
downloads
All versions This version
Views 4,4024,402
Downloads 2,5572,557
Data volume 1.5 GB1.5 GB
Unique views 3,8793,879
Unique downloads 2,3302,330

Share

Cite as